About Fresenius Kabi
Fresenius Kabi is formed by combining Fresenius Group’s Pharma division with the international clinical nutrition business acquired from Pharmacia & Upjohn (Kabi). The new company is Europe’s leader in the field of nutrition and infusion therapy, offering a comprehensive product and service portfolio worldwide for hospitals and patients at home.
Launch of a new generation of hydroxyethyl starch for volume therapy.
Fresenius Kabi’s product portfolio comprises a comprehensive range of I.V. generic drugs, infusion therapies and clinical nutrition products as well as the medical devices for administering these products. Within transfusion technologies, they offer products for collection and processing of blood components and for therapeutic treatment of patient blood by apheresis systems.